IRVINE, Calif., Nov. 7, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, reported today that total revenues for the third quarter and first nine months of 2012 increased to $1.3 million and $3.9 million, respectively, up 5 percent and 14 percent from the third quarter and first nine months of 2011. Revenues from the Company’s core prenatal testing markets in the third quarter grew by 73 percent over the corresponding period in 2011 and grew by more than 76 percent in the first nine months of 2012 over the comparable prior year period. The Company performed a total of 1,356 billable diagnostic tests for 110 customers in the third quarter of 2012, compared to 1,157 tests for 101 customers in the third quarter of 2011.
